Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
15.51
+0.20 (1.31%)
At close: Aug 1, 2025, 4:00 PM
15.54
+0.03 (0.19%)
After-hours: Aug 1, 2025, 4:10 PM EDT
Upstream Bio Revenue
Upstream Bio had revenue of $566.00K in the quarter ending March 31, 2025, with 25.78% growth. This brings the company's revenue in the last twelve months to $2.30M, down -2.94% year-over-year. In the year 2024, Upstream Bio had annual revenue of $2.37M, down -0.42%.
Revenue (ttm)
$2.30M
Revenue Growth
-2.94%
P/S Ratio
178.26
Revenue / Employee
$44,154
Employees
52
Market Cap
835.95M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.37M | -10.00K | -0.42% |
Dec 31, 2023 | 2.38M | 1.17M | 96.37% |
Dec 31, 2022 | 1.21M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionUPB News
- 25 days ago - Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) - GlobeNewsWire
- 6 weeks ago - Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - GlobeNewsWire
- 2 months ago - Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 - GlobeNewsWire
- 2 months ago - Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Upstream Bio Appoints Stacy Price as Chief Technology Officer - GlobeNewsWire
- 3 months ago - Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs - GlobeNewsWire
- 3 months ago - Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent - Seeking Alpha
- 4 months ago - 3 Dividend Giants To Buy As Tariffs Hit Stocks - Benzinga